Visit Lilly.com
Menu closed
Visit Lilly.com
  • House Home
    • Why weight matters in T2D
    • Barriers to weight management in T2D
    • Early glycemic control and weight management in T2D
    • Resource hub for excess weight in T2D
Man lifting weights

Welcome to your excess weight in type 2 diabetes (T2D) RESOURCE HUB

Start by getting answers to your questions about the impact of excess weight in T2D and how to improve patients’ long-term health.

Early intensive glycemic control is associated with a decreased risk of T2D-related complications.1,2 The UKPDS trial* compared newly diagnosed patients with T2D in 2 study groups. Participants were randomly assigned to 1 of 2 treatment regimens: either an intensive treatment regimen to rapidly achieve glycemic control or a more conventional regimen using diet alone.1 Results demonstrated that early intensive glucose therapy reduced the risk of microvascular complications (25%) over 10 years compared with the conventional group.1 The follow-up results from the 10-year post-trial monitoring showed that these reductions were sustained for microvascular risk (24%), and emergent risk reductions for myocardial infarction (15%) were also observed.2

*The UK Prospective Diabetes Study (UKPDS) was designed to establish whether intensive blood glucose control reduced the risk of vascular complications. Between 1977 and 1991, 3867 eligible patients (newly diagnosed with diabetes, 25 to 65 years of age, with a fasting plasma glucose level >6 mmol/L on 2 mornings, 1-3 weeks apart) were randomly assigned to an intensive regimen with treatment or a conventional regimen with diet. The exclusion criteria were: ketonuria more than 3 mmol/L; serum creatinine greater than 175 μmol/L; myocardial infarction in the previous year; current angina or heart failure; more than 1 major vascular event; retinopathy requiring laser treatment; malignant hypertension; uncorrected endocrine disorder; occupation that precluded insulin therapy; severe concurrent illness that would limit life or require extensive systemic treatment; inadequate understanding; and unwillingness to enter the study.1

Excess weight, particularly excess abdominal fat, is associated with insulin resistance in T2D.3-5 Excessive fat accumulation is associated with pathological expansion in adipose depots, adipocyte dysfunction, increase in inflammatory signals, and elevation of plasma lipids.6,7 Additionally, based on animal models, excess circulating lipids may contribute to β-cell dysfunction, which can worsen with T2D.8,9 Therefore, excess weight is a key component in 2 core pathophysiological defects in T2D—insulin resistance and β-cell failure.7,8,10

The American Diabetes Association says, “For many people with T2D, glucose monitoring is key to achieving glycemic targets. In addition, diabetes self-management education and support (DSME/S), medical nutrition therapy (MNT), routine physical activity, smoking cessation counseling when needed, and psychosocial care are essential to achieving diabetes treatment goals and maximizing quality of life.” Click here for resources.11

Use the “6A’s” framework for initiating conversations with patients about obesity management12:

  1. ASK the patient’s permission to address weight
  2. ASSESS the patient’s desired weight-loss goal and reasons for wanting to lose weight
  3. ADVISE the patient about treatment options that align with the patient’s goals and are most likely to help the patient achieve the desired results
  4. AGREE on weight loss, lifestyle, and behavioral goals with the patient
  5. ASSIST the patient by creating a plan
  6. ARRANGE for patient engagement in the treatment plan and close follow-up

Let’s TALK!

Navigating sensitive conversations about weight to support T2D management can be challenging for both HCPs and patients. For examples of collaborative and effective conversations, watch this series of short videos focused on Assessing patient readiness, Advising and educating patients, and Acknowledging the challenges to support patients in their diabetes care journeys.

ASSESS: Evaluating Patient Readiness for Diabetes-Management Strategies


ADVISE: Educating Patients About Addressing Glycemic and Weight Goals

ACKNOWLEDGE: Assisting Patients Through Challenges in Their Diabetes Care Journeys

Medical Workmat

Conversations about weight management in patients with T2D can be challenging. Download the Medical Workmat to help navigate those conversations.


DOWNLOAD

Hear from experts in diabetes care


Addressing Weight in Support of Glycemic Control in People With Type 2 Diabetes

Dr. Alice Cheng, Associate Professor at University of Toronto, Canada

Would you like a summary of all the information you just learned?

DOWNLOAD THE A1C AND WEIGHT OVERVIEW HERE

Additional support

The following resources may be helpful when addressing and managing weight in T2D. These resources are not developed by Eli Lilly and Company and will direct you to an external site.

RESOURCES FOR CLINICIANS

How to Approach Conversations About A1C and Weight:

  • Talking With Patients About Weight Loss: Tips for Primary Care Providers

ADA Resources:

  • Standards of Medical Care in Diabetes
  • Obesity Management for the Treatment of T2D
  • Diabetes Educator Resources

Ethnic Differences in BMI:

  • Differences in BMI and Disease Risk
  • Diabetes Prevalence and BMI Differ by Ethnicity
  • Abdominal Obesity Indirect Measure Guidelines for Different Ethnic Groups

RESOURCES FOR PATIENTS WITH T2D

ADA Resources:

  • Healthy Living and Weight Loss

How to Correctly Measure Waist Circumference:

  • Assessing Weight
  • Assessing Weight and Health Risk

Body-Weight Planner:

  • Body-Weight Planner
  • About the Body-Weight Planner

BMI Calculator:

  • Calculate Body Mass Index
  • Healthy Weight?

References

  1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
  2. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
  3. Cheng Y-H, Tsao Y-C, Tzeng I-S, et al. Body mass index and waist circumference are better predictors of insulin resistance than total body fat percentage in middle-aged and elderly Taiwanese. Medicine (Baltimore). 2017;96(39):e8126.
  4. Racette SB, Evans EM, Weiss EP, Hagberg JM, Holloszy JO. Abdominal adiposity is a stronger predictor of insulin resistance than fitness among 50-95 year olds. Diabetes Care. 2006;29(3):673-678.
  5. Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:22.
  6. Trouwborst I, Bowser SM, Goossens GH, Blaak EE. Ectopic fat accumulation in distinct insulin resistant phenotypes; targets for personalized nutritional interventions. Front Nutr. 2018;5:77.
  7. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008;582(1):97-105.
  8. Ye R, Onodera T, Scherer PE. Lipotoxicity and β cell maintenance in obesity and type 2 diabetes. J Endocr Soc. 2019;3(3):617-631.
  9. Sobczak AIS, Blindauer CA, Stewart AJ. Changes in plasma free fatty acids associated with type-2 diabetes. Nutrients. 2019;11(9):2022.
  10. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
  11. American Diabetes Association Professional Practice Committee. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(suppl 1):S77-110. doi:10.2337/dc24-S005.
  12. Tucker S, Bramante C, Conroy M, et al. The most undertreated chronic disease: addressing obesity in primary care settings. Curr Obes Rep. 2021;10(3):396-408.
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

 

PP-LD-US-2850 12/2024 © Lilly USA, LLC 2024. All rights reserved.

Your Privacy Choices

Cookie Settings

Terms of Use Privacy Statement Consumer Health Privacy Notice Accessibility Statement Sitemap
Visit Lilly.com